epiClinical is fictional. It is a portfolio demonstration by Adam Daniels. Its studies, sponsors, sites and enrolment figures are synthetic. The evidence behind its assumptions is real, and every number says how far it can be trusted.
EPI-620, Phase III. In planning
Chronic obstructive pulmonary disease with frequent exacerbations
LWR-620 against placebo to reduce exacerbations in COPD. Sponsor: Litware Respiratory (fictional), Respiratory.
The QTLs this study should set before its first patient, in priority order. Their charts start once patients are randomised.
Rank
QTL
Likelihood
Impact
Why it is likely here
Watched at sites by
Warning
Limit
Critical
1
Stopped study treatment earlyEvidence grade B
3
2
Placebo or no-added-treatment control arm (PD-05)From the design: What does the control arm receive? Placebo or no added treatment
Study drug at the siteTighter KRI threshold at sites in Turkey, for currency crisis with a fixed pharmaceutical exchange rate (Turkey 2018–2026). The QTL itself stays study-wide.
12.5%
15%
22%
2
Ineligible patients randomisedEvidence grade B
2
2
Comorbidity exclusions (PD-15)From the design: Does the protocol exclude common comorbidities? Yes
Restrictive eligibility criteria and protocol complexity (EB-04)From the design: How many non-essential exclusions does the protocol carry? One or two
Eligibility criteria exclude patients (comorbidity, age, performance status, language) (PB-02)From the design: How many non-essential exclusions does the protocol carry? One or two; Does the protocol exclude common comorbidities? Yes
Restrictive eligibility criteria (organ function, brain metastases, prior or concurrent malignancy, HIV, laboratory thresholds, performance status) (PD-01)From the design: How many non-essential exclusions does the protocol carry? One or two
Number of eligibility criteria and complexity growth (PD-02)From the design: How many non-essential exclusions does the protocol carry? One or two
Critical lines assume each study was designed for 80% power at a two-sided 5% level, and mark where power would fall to 70%. Missing outcome data can bias a result well before it costs power, so its limit, not its critical line, is the one to act on.